Tesofensine for Weight Loss: Dosage, Results & Side Effects

Tesofensine: A Different Approach to Weight Loss

Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor originally developed by NeuroSearch as a treatment for Parkinson's disease and Alzheimer's disease. During those early neurological trials, researchers noticed a striking side effect: participants were losing substantial amounts of weight. This serendipitous observation redirected tesofensine's development toward obesity, where it produced some of the most impressive weight loss results ever seen for an oral appetite suppressant in phase 2 trials. This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before considering any weight-loss compound.

We cover tesofensine on Peptides Insider because it occupies the same functional space as GLP-1 agonists and other weight loss compounds our readers are researching. Understanding how tesofensine works — and why it has not reached the market despite strong efficacy data — provides important context for anyone evaluating weight management options.

Mechanism of Action

Tesofensine inhibits the reuptake of three monoamine neurotransmitters simultaneously:

• Serotonin (5-HT). Serotonin reuptake inhibition contributes to satiety signaling. This is the same mechanism exploited by fenfluramine and lorcaserin, both of which produced weight loss through serotonergic appetite suppression.
• Norepinephrine (NE). Norepinephrine reuptake inhibition increases sympathetic nervous system activity, which raises basal metabolic rate and energy expenditure. This thermogenic effect means tesofensine promotes weight loss not only by reducing intake but also by increasing caloric burn — similar in concept to the glucagon component of retatrutide.
• Dopamine (DA). Dopamine reuptake inhibition affects reward circuitry and motivation. By modulating dopaminergic tone, tesofensine may reduce food cravings and the hedonic drive to eat — the "wanting" component of eating behavior that pure appetite suppressants do not fully address.

This triple reuptake inhibition distinguishes tesofensine from selective compounds like SSRIs (serotonin only), bupropion (norepinephrine and dopamine), or phentermine (primarily norepinephrine)^[1].

Pharmacokinetics

Tesofensine is orally bioavailable with a long half-life (~200-300 hours), allowing once-daily dosing. It is metabolized to its active metabolite (M1), which has an even longer half-life. Steady-state levels are reached over several weeks, and effects persist for an extended period after discontinuation.

Phase 2 Clinical Trial Results

The pivotal Phase 2 trial (TIPO-1) was a 24-week, randomized, double-blind, placebo-controlled study in 203 obese subjects (BMI 30-40 kg/m2)^[1]:

Dose	Mean Weight Loss	Placebo-Subtracted	Responders (5% or more)
Placebo	-2.2%	—	29%
0.25 mg daily	-6.7%	-4.5%	59%
0.5 mg daily	-11.3%	-9.1%	87%
1.0 mg daily	-12.8%	-10.6%	89%

The 12.8% mean body weight loss at the 1.0 mg dose over just 24 weeks was remarkable, particularly for an oral compound. For context, semaglutide 2.4 mg achieved 14.9% weight loss but over 68 weeks. The rate of weight loss with tesofensine was substantially faster.

Metabolic Benefits Beyond Weight Loss

The Phase 2 data also showed improvements in metabolic markers:

• Waist circumference: Significant reduction across all doses
• Triglycerides: Decreased by 15-20%
• Insulin sensitivity: Improved (HOMA-IR)
• Adiponectin: Increased (favorable for metabolic health)
• hsCRP: Decreased (indicating reduced systemic inflammation)

Side Effects and Safety Concerns

Despite impressive efficacy, tesofensine's side effect profile — particularly cardiovascular effects — has been the primary barrier to its development.

Cardiovascular Effects

• Increased heart rate: Mean increases of 7-8 bpm (dose-dependent). This is clinically significant and distinguishes tesofensine from GLP-1 agonists, which have neutral or mildly beneficial cardiovascular profiles.
• Blood pressure: Although systolic blood pressure decreased with weight loss, the effect was attenuated compared to what would be expected from the magnitude of weight loss alone.
• Dry mouth: 33-48% of participants (most common side effect)

The cardiovascular concerns are not theoretical. The history of obesity pharmacology includes withdrawn drugs that raised cardiovascular risk: fenfluramine/dexfenfluramine (valvular heart disease), sibutramine (cardiovascular events). Regulators have become extremely cautious about any obesity drug that raises heart rate.

Psychiatric and CNS Side Effects

• Insomnia: 15-25% reported difficulty sleeping, consistent with NE and DA reuptake inhibition
• Mood changes: Generally positive (improved mood/energy), but monitoring required
• Headache: 10-15%
• Constipation: 12-18%

For a comprehensive overview of side effects associated with various weight loss compounds, see our peptide side effects guide.

Tesofensine vs GLP-1 Receptor Agonists

Feature	Tesofensine (0.5 mg)	Semaglutide (2.4 mg)	Tirzepatide (15 mg)
Administration	Oral, daily	Injectable, weekly	Injectable, weekly
Mechanism	Triple monoamine reuptake inhibitor	GLP-1 agonist	GLP-1/GIP dual agonist
Weight Loss (best dose)	~12.8% (24 wk)	~14.9% (68 wk)	~22.5% (72 wk)
CV Effect on HR	Increase (+7-8 bpm)	Neutral/mild increase	Neutral
GI Side Effects	Mild (dry mouth, constipation)	Significant (nausea 44%)	Significant
CV Outcome Trial	None	SELECT (positive)	Pending
FDA Status	Not approved	Approved	Approved

The key takeaway: tesofensine produces rapid and substantial weight loss, potentially faster than semaglutide in the early weeks. However, it lacks the cardiovascular benefits, glycemic improvements, and cardiovascular outcome trial data that have made GLP-1 agonists the cornerstone of modern obesity treatment.

Current Development Status

• 2008: Phase 2 results published showing impressive weight loss
• 2010-2015: NeuroSearch (original developer) faced financial difficulties; rights licensed to Saniona
• 2018-present: Medix (Mexico) developed tesofensine as Agenix/Obesidat for the Mexican and Latin American markets
• 2024-2026: Renewed interest for combination therapies and specific populations

Tesofensine was approved in Mexico under the brand name Obesidat (in combination with metformin). It is not approved by the FDA, EMA, or most other major regulatory agencies. Some compounding pharmacies offer tesofensine, though this exists in a regulatory gray area.

Dosing Protocols

Based on the available clinical data:

• Starting dose: 0.25 mg once daily, taken in the morning
• Therapeutic dose: 0.5 mg once daily (best balance of efficacy and side effects)
• Maximum studied dose: 1.0 mg once daily (slightly better weight loss but more side effects)
• Timing: Morning administration to minimize insomnia

The 0.5 mg dose is generally considered the optimal balance, producing 11.3% weight loss with fewer cardiovascular effects than the 1.0 mg dose. For broader dosing principles, see our peptide dosage guide.

Combination Potential

Because tesofensine's mechanism is entirely different from GLP-1 agonists, there is theoretical rationale for combination protocols:

• Tesofensine + GLP-1 agonist: Dual appetite suppression through complementary pathways
• Tesofensine + AOD-9604: Central appetite/metabolism enhancement plus direct lipolysis
• Tesofensine + tesamorelin: Appetite control plus GH-mediated visceral fat reduction

However, no controlled clinical trials have evaluated these combinations. Combining a monoamine reuptake inhibitor with other pharmacological agents requires careful medical supervision.

Safety Warnings and Contraindications

Tesofensine should be avoided or used with extreme caution in:

• Uncontrolled hypertension or cardiovascular disease
• History of stroke or transient ischemic attack
• Concurrent use of MAO inhibitors or other monoamine-active drugs
• History of glaucoma (due to sympathomimetic effects)
• Anxiety disorders (may exacerbate symptoms)
• Pregnancy or breastfeeding

The Bottom Line

Tesofensine is a pharmacologically fascinating compound that produced impressive weight loss in phase 2 trials — comparable to early GLP-1 results in a shorter timeframe. Its triple monoamine reuptake mechanism provides appetite suppression, increased energy expenditure, and reduced food reward signaling in a single oral pill. However, cardiovascular side effects and the lack of outcome trial data have prevented it from reaching major markets. It remains available in limited markets and through compounding channels, but is not a first-line recommendation for most individuals seeking weight loss.